Application of a synthetic nicotine analogue as a nicotine alternative
By using the synthetic nicotine analog (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine organic acid salt in novel tobacco products, the physiological dependence and local irritation problems of nicotine alternatives have been solved, resulting in a healthier, smoother smoking experience and reduced lung health risks.
Patent Information
- Application Number
- CN202611126899.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-28
- Publication Date
- 2026-11-17
AI Technical Summary
Existing nicotine alternatives cannot completely eliminate physiological dependence, and they suffer from local irritation and high barriers to use. Furthermore, the combustion of traditional tobacco produces carcinogens that are harmful to health.
Synthetic nicotine analogues (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine or their organic acid salts, such as tartrates and resin salts, are used in novel tobacco products such as e-cigarettes, heated tobacco products, and oral cigarettes. They are absorbed orally or through the digestive tract, avoiding high-temperature pyrolysis products and lung damage.
It reduces the irritation and discomfort caused by nicotine, lowers the risk of lung damage, avoids the production of carcinogenic byproducts, and provides a smoother experience with lower health risks.
Smart Images

Figure CN123100869A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the technical field of novel tobacco products, and in particular relates to the application of a synthetic nicotine analogue as a nicotine substitute. Background Technology
[0002] Traditional tobacco generally refers to tobacco products that are smoked, chewed, or smelled by burning tobacco leaves. The most common forms include cigarettes, cigars, pipe tobacco, and snuff. As a widely used consumer product globally, traditional tobacco has a history of use spanning thousands of years, forming a unique industrial chain and culture. The core reason for the widespread use of traditional tobacco lies in its nicotine content. Nicotine acts on the central nervous system, producing a temporary feeling of excitement and pleasure, but it also poses significant health risks, acting as a driving force behind continuous exposure to carcinogens. Furthermore, its toxicity to the cardiovascular, nervous, metabolic, and reproductive systems is equally undeniable. Quitting smoking completely is the only effective way to escape the harms of nicotine.
[0003] In an article (International Journal for Parasitology: Drugs and Drug Resistance 7 (2017) 12-22), some scholars discussed the activation mechanism of nicotine acetylcholine receptors (nAChRs) and the types of compounds that can activate acetylcholine receptors: acetylcholine (ACh), nicotine and nicotine structural analogs. Using nicotine acetylcholine receptors (nAChRs) from the swine ascarid as drug targets, the pharmacological activities of nicotine and nicotine analogs binding to nicotine acetylcholine receptors (nAChRs) were studied at the cellular and molecular level. The EC50 (μM) values of nicotine, acetylcholine, 2-methyl-5-(1-methylpyrrolidone-2-yl)pyridine, and 3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine were 6.36±0.49, 6.21±0.56, 6.13±0.53, and 0.99±0.17, respectively.
[0004] This study demonstrates that 3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine exhibits six times the activity of nicotine at the cellular molecular level. Furthermore, (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine, as the active component in the racemic mixture, exhibits superior pharmacological activity. In addition, the team compared the toxicity of other nicotine derivatives, showing that (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine has relatively lower toxicity than nicotine, indicating promising potential for use in nicotine addiction intervention and neurodegenerative diseases.
[0005] Limitations of nicotine replacement therapy (legitimate products): Nicotine replacements cannot completely eliminate physiological dependence, and different types have technical defects such as local irritation and usage barriers.
[0006] While these products (such as patches, chewing gum, and lozenges) are safer than smoking directly, they still have significant shortcomings in actual use.
[0007] It's difficult to completely wean off nicotine. These products only change the way nicotine is ingested and cannot completely block the brain's reward memory of nicotine. Some people may use them for a long time or even be unable to quit completely. Local adverse reactions include contact dermatitis caused by patches, leading to redness, swelling, and itching of the skin; and nausea, hiccups, burning sensation in the mouth, or jaw joint pain if chewing gum and lozenges are used improperly (such as swallowing too much).
[0008] The usage threshold is relatively high: different dosage forms have strict operating requirements. For example, chewing gum requires a specific rhythm of "chewing a few times and pausing for a few minutes," otherwise the nicotine will be broken down by stomach acid and become ineffective; nasal sprays may cause nasal irritation symptoms such as sneezing and runny nose.
[0009] Therefore, finding satisfactory and effective nicotine alternatives remains a significant challenge in this rapidly developing emerging tobacco industry. Summary of the Invention
[0010] The purpose of this invention is to address the shortcomings of existing technologies by proposing the application of synthetic nicotine analogues as nicotine substitutes, especially in the research and development of new tobacco formulations. Test results show that these analogues have significant detoxification effects, a smoother experience, reduced irritation and discomfort, and a lower risk of lung damage.
[0011] To achieve the above objectives, the specific technical solution adopted by the present invention is as follows:
[0012] The use of a synthetic nicotine analog in nicotine alternatives, characterized in that the synthetic nicotine analog comprises (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine (Formula I) or (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine organic acid salt.
[0013] Preferably, the (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine organic acid salt is (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine tartrate (Formula II) or (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine resin salt (Formula III).
[0014]
[0015] Preferably, the application of the synthetic nicotine analogue in nicotine substitutes is in the form of novel tobacco products.
[0016] Preferably, the novel tobacco product is one of electronic cigarettes, heated tobacco products, oral cigarettes, nicotine substitutes, or other emerging dosage forms.
[0017] The beneficial effects of this invention are:
[0018] This invention utilizes (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine or (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine organic acid salts as nicotine substitutes in novel tobacco products such as e-cigarettes, heated tobacco products, oral cigarettes, nicotine replacement formulations, or other emerging formulations. Its advantages are:
[0019] 1) Get rid of tobacco toxins
[0020] As a synthetic substance, the nicotine analogue in this invention contains no tar and no carcinogenic byproducts produced during the combustion of conventional tobacco.
[0021] 2) Smoother experience, reducing irritation and discomfort
[0022] The nicotine analogues in this invention provide a smoother effect than traditional nicotine, without the sharp, lingering sensation or intense cravings associated with traditional nicotine. Furthermore, due to their milder irritation to the digestive system, they can be gently absorbed through the mouth or stomach, avoiding the adverse reactions such as throat irritation, stomach swelling and pain, and vomiting that can occur with high-concentration nicotine.
[0023] 3) Reduce the risk of lung damage
[0024] By changing the route of intake to oral administration or absorption through the digestive tract, the nicotine analogue in this invention can completely eliminate the lung damage caused by tar in traditional cigarettes and substances such as glycerol and propylene glycol commonly found in e-cigarettes. Compared to combustion aerosols, it has no high-temperature pyrolysis products, significantly reducing the lung health risks associated with smoking. Attached Figure Description
[0025] Figure 1 : Purity spectrum of (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine tartrate.
[0026] Figure 2 Chiral spectrum of (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine tartrate.
[0027] Figure 3 Chiral spectrum of (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine resin salt. Detailed Implementation
[0028] The preparation method of (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine, i.e. 5-methylnicotine, used in the following examples is a patent previously applied for by our company, patent application number 202510781601.9 (patent publication number CN120555531A).
[0029] Example 1: Synthesis of (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine tartrate
[0030] The reaction equations involved in this embodiment are as follows:
[0031]
[0032] The proportions of raw materials and solvents involved in this embodiment are shown in the table below:
[0033]
[0034] Synthesis steps:
[0035] 1) Introduce nitrogen into the salt formation reactor and evacuate it. Replace the air in the reactor with nitrogen and vacuum three times to ensure an inert nitrogen protective atmosphere inside the reactor.
[0036] 2) Use a diaphragm pump to pump 1500L of ethanol / purified water (volume ratio 9:1) mixed solvent into the reaction vessel after displacement.
[0037] 3) Control the temperature range of the reactor to 15-30℃, add 170.03 kg of L-tartaric acid into the reactor; after the addition is completed, raise the temperature to 60-65℃, keep the temperature constant and stir for 1 hour until the L-tartaric acid is completely dissolved to obtain a clear acidic solution.
[0038] 4) Maintain nitrogen protection inside the reactor and system temperature at 60-65℃. Use a brand new diaphragm pump to quickly add 100kg of (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine, i.e. 5-methylnicotine, to the above tartaric acid solution. Nitrogen is used to isolate the system from air throughout the feeding process.
[0039] 5) Under nitrogen protection, the reaction system is cooled to 35-40℃ at a constant rate; a small amount of 5-methylnicotine L-tartrate seed crystals are added to the system and stirred at a constant temperature for 1-2 hours, and a large amount of white solid crystals precipitate out of the system.
[0040] 6) Maintain nitrogen protection and continuously reduce the system temperature at a cooling rate of 10℃ / h; after the system temperature drops to 15-30℃, stir at a constant temperature for 2 hours to allow for full crystallization.
[0041] 7) Transfer all solid-liquid mixture in the vessel to a centrifuge for centrifugation and filtration, and collect the resulting solid wet product.
[0042] 8) Transfer the wet product to a forced-air drying oven, set the drying temperature to 40-45℃, and dry it to constant weight.
[0043] 9) Finished Product Discharge: After drying, the product is discharged, weighed, and sampled for testing to obtain the target product (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine tartrate (ANH-025-D). The purity spectrum of (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine tartrate is shown below. Figure 1 As shown, the chiral spectrum is as follows Figure 2 As shown.
[0044] Test data: KF=9.4%; Purity: 100.00%; No ND for single impurities; No ND for total impurities; Chiral purity: 99.78%; Content: 100.00%; Ethanol residue not detected.
[0045] Example 2: Synthesis of (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine resin salt
[0046] The reaction equations involved in this embodiment are as follows:
[0047]
[0048] The proportions of raw materials and solvents involved in this embodiment are shown in the table below:
[0049]
[0050] Synthesis steps:
[0051] 1) Add 200L of purified water to a 1000L reactor and turn on the stirring device inside the reactor. Add 70kg of pre-activated D155 acrylic wet ion exchange resin to the reactor opening, control the system temperature at 20-30℃, and stir at a constant temperature for 2-3 hours to fully disperse the resin in the water.
[0052] 2) Maintain the system temperature at 20-30℃ and use a diaphragm pump to add 20kg of 5-methylnicotine to the reaction system in step 1).
[0053] 3) Transfer all the resin mixture in the reactor to a centrifuge for centrifugation until no free liquid flows out; use purified water to rinse the resin solid obtained by centrifugation to remove unadsorbed free raw material impurities.
[0054] 4) After rinsing, discharge the material and transfer the centrifuged wet resin into a PE packaging bag for temporary storage.
[0055] 5) Transfer all the wet resin in the PE bag to the mixer, slowly add 10 kg of glycerin, and stir for 1-2 hours to make the glycerin evenly coat the resin particles.
[0056] 6) Transfer the mixed wet resin to a forced-air drying oven for drying; control the drying temperature at 40-45℃ and the drying time at 24-48 hours until the material moisture content KF ≤ 5.0%, obtaining the target product (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine resin salt. The chiral spectrum of (S)-3-methyl-5-(1-methylpyrrolidone-2-yl)pyridine resin salt is shown below. Figure 3 As shown.
[0057] Test data: KF=4.38%; purity: 99.92%, single impurity 0.05%, total impurities 0.08%, glycerol content 22.84%, content 19.85%.
[0058] Example 3: 5-Methylnicotine oral coating
[0059] The raw materials, solvents, specifications, and feeding ratios used in this embodiment are shown in the table below:
[0060]
[0061] Preparation steps
[0062] 1. Mixing and stirring process:
[0063] 1) Heat the mixture in a water bath to 90°C and start stirring (180-210 rpm / min). Weigh 160g of purified water and add it to a beaker. Heat to 90°C and add 17.5g of polyvinyl alcohol (PVA) in batches, stirring for 2 hours until completely dissolved to prepare a polyvinyl alcohol solution. (The gel should be clear and transparent for an extended period, without any white or transparent lumps.)
[0064] 2) Cool the water bath to 75°C, weigh 50g of hydroxypropyl methylcellulose and mix it evenly. Weigh 120g of purified water and heat it to 90°C. Add the hydroxypropyl methylcellulose to the polyvinyl alcohol solution in batches, while adding the purified water in batches to prevent the hydroxypropyl methylcellulose from clumping. Dissolve the hydroxypropyl methylcellulose by stirring at a speed of 210-300 rpm / min.
[0065] 3) Weigh 15g of purified water, add 7.5g of polyethylene glycol, heat and stir until dissolved, and add to the mixture from step 2.
[0066] 4) Weigh 15g of sorbitol, 5g of glycerol, and 0.5g of Tween 80 and add them to the mixture in step 2 in sequence, and stir for 1.5 hours.
[0067] 5) Remove the water bath, continue stirring and cool to room temperature, weigh the raw material 5-methylnicotine, replenish the lost purified water, and finally obtain the prepared base material.
[0068] 2. Defoaming process
[0069] The prepared medicated adhesive is transferred to a vacuum degassing machine and degassed according to a five-stage procedure to eliminate air bubbles inside the adhesive solution.
[0070] First stage: No vacuum, 600 rpm, stirring for 30 seconds;
[0071] Second stage: Vacuum degree 90Kpa, rotation speed 800rpm, stirring for 1min;
[0072] Third stage: Vacuum degree 90Kpa, rotation speed 1200rpm, stirring for 2min;
[0073] Fourth stage: Vacuum degree 90 kPa, rotation speed 800 rpm, stirring for 30 seconds;
[0074] Fifth stage: No vacuum, 90 kPa, 400 rpm, stirring for 30 seconds;
[0075] After degassing, a bubble-free homogeneous coated adhesive is obtained.
[0076] 3. Film-forming process:
[0077] Film forming machine settings: Zone 1 drying tunnel set temperature 80℃ (actual operating temperature 60℃), Zone 2 drying tunnel set temperature 85℃ (actual operating temperature 65℃); coating thickness 0.7mm, coating film speed 0.1m / min; Zone 1 fan frequency 25Hz, Zone 2 fan frequency 35Hz; Zone 1 exhaust frequency 40Hz, Zone 2 exhaust frequency 40Hz.
[0078] The degassed medicated adhesive is poured into the material tank of the film-forming machine, and a 2m long film is continuously coated. After being dried by hot air in two drying tunnels, it is peeled off and rolled up to obtain the finished 5-methylnicotine oral solution film.
[0079] Finished product quality inspection results:
[0080] Testing items Test results Color Translucent, uniform color form A translucent, sheet-like film with no obvious air bubbles. feel The membrane is intact and smooth, with uniform thickness, and good strength and toughness. taste Under the given formulation and processing conditions, 5-methylnicotine oral dissolving film forms a soft film with minimal throat-locking sensation, a strong intoxicating effect, and a rich minty flavor and aroma. Thickness / mm 0.08~0.09mm Content (theoretical) 7.532%
[0081] Example 4: 5-Methylnicotine Resin Salt Chewing Gum
[0082] The raw materials, solvents, specifications, and feeding ratios used in this embodiment are shown in the table below:
[0083]
[0084] Preparation steps
[0085] 1. Mixing and stirring process:
[0086] 1) The chewing gum mixing machine rotates at 35 Hz and is kept at 40 ℃. Weigh out the materials in the experimental formula (except for gum base, flavoring and menthol) in sequence and add them to the mixing machine and stir for 0.15 h.
[0087] 2) Weigh 661g of rubber base and place it in a forced-air drying oven (temperature set at 50℃) to bake for 0.5h until the rubber base is completely softened. After taking it out, add it to the mixer in batches and stir for 0.3~0.5h until the rubber base and solid materials are evenly mixed and flocculent. Then turn off the mixer to keep it warm and the circulating pump.
[0088] 3) Weigh 10g of menthol, heat it to a liquid state, and add it to the mixture in step 2.
[0089] 4) Weigh 30g of flavoring and add it to the mixture in step 2, then stir for 0.15h.
[0090] 5) Stop stirring and scoop out the mixture after it has cooled to room temperature.
[0091] 2. Extrusion tableting process
[0092] The mixture prepared above was added to the feed port of the extruder in batches to prepare long strip-shaped raw materials for chewing gum. The parameters of the chewing gum extruder were set as follows: forward rotation 35Hz, heat preservation heating 40℃.
[0093] 3. Molding and slitting process
[0094] Sprinkle a small amount of talcum powder evenly on the pressure rollers, blades, and guide rails of the forming and slitting machine. Sprinkle talcum powder evenly on both sides of the long strip of raw material obtained by extrusion, and place it into the track of the forming and slitting machine in sections for compaction and slitting.
[0095] 4. Freezing and pelletizing, drying and dehumidification, packaging
[0096] The raw materials obtained above are frozen in a refrigerator for 0.5 hours, taken out and divided into sugar blanks. The sugar blanks are spread evenly on a tray, placed in a dehumidification room, and dehumidified for 24 hours. They are then packaged and shaped according to commercial packaging conditions.
[0097] Finished product quality inspection results:
[0098] Testing items Test results Color milky form Smooth surface feel The sugar dough is relatively hard and not easily deformed. taste It has a sweet taste and a distinct aroma, with minimal throat-soothing sensation and a strong intoxicating effect. Particle weight / g 1.43 Content / mg 8.58
[0099] Example 5: 5-Methylnicotine Spray
[0100] The raw materials, solvents, specifications, and feeding ratios used in this embodiment are shown in the table below:
[0101]
[0102] Preparation steps
[0103] 1. Weigh 100.00g of purified water and add it to a beaker. Weigh 0.01g of trifolin and 0.10g of neohesperidin dihydrochalcone and add them to the mixed solution in step 1. Stir until dissolved (there should be no visible solids or particles in the solution).
[0104] 2. Weigh 4.00g of hydroxypropyl-β-cyclodextrin and add it to the mixed solution in step 4. Stir until dissolved (no visible particles).
[0105] 3. Weigh 7.00g of peppermint flavoring, 0.30g of cooling agent, and dissolve (no visible particles) and add to the mixed solution from step 2. Stir for 0.3 hours, then bottle for spray testing.
[0106] Finished product quality inspection results:
[0107] Test Project 025 Spray (Peppermint H570) Color and form transparent liquid taste It has a cool, sweet taste, a noticeable intoxicating effect, and a strong minty flavor. Spray weight / time 0.025g Single dose content (theoretical) 0.295mg
[0108] Example 6: 5-Methylnicotine tartrate tablet preform / mint flavor
[0109] The raw materials, solvents, specifications, and feeding ratios used in this embodiment are shown in the table below:
[0110]
[0111] Preparation steps
[0112] 1. Weigh out each of the ingredients in the formula table and place them in a PE bag. Shake well.
[0113] 2. Grind the materials from step 1 in batches until no large particles remain, and then place them in a stainless steel tray for later use.
[0114] 3. Place the sugar preform raw material from step 2 into a tablet press, pressurize to 400 bar, let stand for 2 seconds, release the pressure and remove the sugar preform, and conduct a sensory evaluation of the appearance, taste and melting time of the sugar preform.
[0115] Finished product quality inspection results:
[0116] Inspection items Test results (1.5g / capsule) Color White form Smooth surface feel Smooth surface taste The peppermint candy base has a strong initial effect, minimal throat irritation, a distinctly sweet and cool taste, and a suitable firmness that prevents it from crumbling. Melting time About 10 minutes Sugar granule weight / mg 1.48~1.52g Single tablet content / mg No API
[0117] Example 7: 5-Methylnicotine resin salt lozenge
[0118] The raw materials, solvents, specifications, and feeding ratios used in this embodiment are shown in the table below:
[0119]
[0120] The steps for preparing a mouth bag are as follows:
[0121] Step 1: Mix microcrystalline cellulose, acesulfame potassium, mannitol and sodium carbonate evenly to obtain mixture A.
[0122] Step 2: Mix peppermint essence, nicotine resin salt, glycerin and water, then add to mixture A and stir continuously for 30 minutes to achieve a fully mixed state, resulting in a homogeneous mixture B.
[0123] Step 4: Fill the non-woven bag with filler B to obtain a mouth bag containing 5-methylnicotine resin salt.
[0124] Finished product quality inspection results:
[0125] Testing items Test results Color White powder form Non-woven bags Powder leakage No powder leakage taste It has a sweet taste and a distinct aroma, with minimal throat-straining, a strong intoxicating effect, and a moderate level of dryness in the mouth. Particle weight / g 700mg Content / mg 6.12
[0126] Those skilled in the art will understand that although specific embodiments of the invention have been described herein for illustrative purposes, various modifications can be made thereto without departing from the spirit and scope of the invention. Therefore, the specific embodiments and examples of the invention should not be considered as limiting the scope of the invention. The invention is limited only by the appended claims. All documents referenced in this application are incorporated herein by reference in their entirety.
Claims
1. Use of a synthetic nicotine analogue in a nicotine replacement product, characterized in that, The synthetic nicotine analog comprises (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)pyridine or (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)pyridine organic acid salt.
2. Use according to claim 1, characterized in that, The (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)pyridine organic acid salt is (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)pyridine tartrate or (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)pyridine resin salt.
3. Use according to claim 1, characterized in that, The use of the synthetic nicotine analog in a nicotine replacement product is use in a novel tobacco product.
4. Use according to claim 3, characterized in that, The novel tobacco product is one of an electronic cigarette, a heat-not-burn tobacco product, a chewing tobacco, a nicotine replacement dosage form, or other emerging dosage form.
Citation Information
Patent Citations
Method for preparing (S)-3-methyl-5-(1-methylpyrrole-2-yl) pyridine from imine reductase mutant
CN120555531A
